Tivic Health Systems Inc (TIVC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tivic Health Systems Inc (TIVC) has a cash flow conversion efficiency ratio of -0.453x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.01 Million) by net assets ($11.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tivic Health Systems Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Tivic Health Systems Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tivic Health Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tivic Health Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tivic Health Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mobico Group Plc
LSE:MCG
|
-1.446x |
|
Duke Royalty Ltd
LSE:DUKE
|
0.039x |
|
NEVADA SUNRISE METALS
F:K4L
|
-0.750x |
|
Antler Gold Inc
V:ANTL
|
0.002x |
|
Purple Biotech
NASDAQ:PPBT
|
-0.108x |
|
Streamline Health Solutions Inc
NASDAQ:STRM
|
-0.088x |
|
Ordinary Fully Paid Deferred Settlement
AU:CDEDC
|
N/A |
|
Arbuthnot Banking Group Plc
LSE:ARBB
|
0.304x |
Annual Cash Flow Conversion Efficiency for Tivic Health Systems Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tivic Health Systems Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Tivic Health Systems Inc (TIVC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-7.00 Million | -0.417x | +81.55% |
| 2024-12-31 | $2.54 Million | $-5.72 Million | -2.258x | +5.01% |
| 2023-12-31 | $3.58 Million | $-8.51 Million | -2.377x | +3.24% |
| 2022-12-31 | $3.63 Million | $-8.92 Million | -2.457x | -481.07% |
| 2021-12-31 | $13.27 Million | $-5.61 Million | -0.423x | -116.44% |
| 2020-12-31 | $-1.18 Million | $-3.03 Million | 2.572x | +266.15% |
| 2019-12-31 | $2.37 Million | $-3.67 Million | -1.548x | -- |
About Tivic Health Systems Inc
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offe… Read more